A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- THERANOSTICS10(12) · pp.5181 · 2020
- 피인용
- Web of Science 21Scopus 22
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 8.579
- ISSN
- 1838-7640
저자
- Lim, Minji제1저자Center for Soft and Living Matter, Institute for Basic Science (IBS), Ulsan 44919, Republic of Korea
- Park, JuheeCenter for Soft and Living Matter, Institute for Basic Science (IBS), Ulsan 44919, Republic of Korea
- Lowe, Alarice C.Department of Pathology, Stanford University, Stanford, CA, 94305, USA
- Jeong, Hyoung-OhDepartment of Biomedical Engineering, School of Life Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Republic of Korea
- Lee, SeminDepartment of Biomedical Engineering, School of Life Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Republic of Korea
- Park, Hee ChulClinomics Inc., Ulsan 44919, Republic of Korea
- Lee, KyusangClinomics Inc., Ulsan 44919, Republic of Korea
- 김광하Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, 179, Gudeok-ro, Seo-Gu, Busan 49241, Republic of Korea
- 김미현교신저자Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, 179, Gudeok-ro, Seo-Gu, Busan 49241, Republic of Korea
- Cho, Yoon-Kyoung교신저자Center for Soft and Living Matter, Institute for Basic Science (IBS), Ulsan 44919, Republic of Korea
초록
Rationale: Unlike traditional biopsy, liquid biopsy, which is a largely non-invasive diagnostic and monitoring tool, can be performed more frequently to better track tumors and mutations over time and to validate the efficiency of a cancer treatment. Circulating tumor cells (CTCs) are considered promising liquid biopsy biomarkers; however, their use in clinical settings is limited by high costs and a low throughput of standard platforms for CTC enumeration and analysis. In this study, we used a label-free, high-throughput method for CTC isolation directly from whole blood of patients using a standalone, clinical setting-friendly platform. Methods: A CTC-based liquid biopsy approach was used to examine the efficacy of therapy and emergent drug resistance via longitudinal monitoring of CTC counts, DNA mutations, and single-cell-level gene expression in a prospective cohort of 40 patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. Results: The change ratio of the CTC counts was associated with tumor response, detected by CT scan, while the baseline CTC counts did not show association with progression-free survival or overall survival. We achieved a 100% concordance rate for the detection of EGFR mutation, including emergence of T790M, between tumor tissue and CTCs. More importantly, our data revealed the importance of the analysis of the epithelial/mesenchymal signature of individual pretreatment CTCs to predict drug responsiveness in patients. Conclusion: The fluid-assisted separation technology disc platform enables serial monitoring of CTC counts, DNA mutations, as well as unbiased molecular characterization of individual CTCs associated with tumor progression during targeted therapy.
키워드
circulating tumor cellssingle cell analysisgene expressionEGFR mutationnon-small cell lung cancerLUNG-CANCERPROGNOSTIC-SIGNIFICANCEGENE-EXPRESSIONCELLSSURVIVALBLOODEMTOSIMERTINIBRESISTANCEINHIBITORS
식별자
- Scopus EID
- 2-s2.0-85083823433
- WoS UID
- 000526083000002



로그인
연구물 목록으로